{
  "question_stem": {
    "en": "Pharmacologic researchers develop a novel alkylating chemotherapeutic agent against glioblastoma multiforme. They find that malignant cells with methylation of the promoter region for the O6-methylguanine-DNA methyltransferase (*MGMT*) gene are more susceptible to this drug than cells *without* methylation. Which of the following is the most likely function of the protein encoded by the gene? {{exhibit_1}}",
    "zh": "药理学研究人员开发了一种新型烷化化疗药物，用于治疗多形性胶质母细胞瘤。他们发现，与*未*甲基化的细胞相比，O6-甲基鸟嘌呤-DNA甲基转移酶 (*MGMT*) 基因启动子区域发生甲基化的恶性细胞对该药物更敏感。以下哪项最可能是该基因编码的蛋白质的功能？ {{exhibit_1}}"
  },
  "question": {
    "en": "Which of the following is the most likely function of the protein encoded by the gene?",
    "zh": "以下哪项最可能是该基因编码的蛋白质的功能？"
  },
  "options": {
    "A": {
      "en": "Induction of apoptosis",
      "zh": "诱导细胞凋亡"
    },
    "B": {
      "en": "Reducing major histocompatibility complex expression",
      "zh": "减少主要组织相容性复合体表达"
    },
    "C": {
      "en": "Repairing DNA damage",
      "zh": "修复 DNA 损伤"
    },
    "D": {
      "en": "Upregulation of telomerase",
      "zh": "上调端粒酶"
    }
  },
  "correct_answer": "C",
  "explanation": {
    "en": "Neoplasms develop genetic alterations that promote cellular growth and survival. Although this is partially mediated by inactivating genetic mutations in tumor suppressor genes (eg, p53), much of oncogenesis is mediated by the *altered expression* of unmutated genes, as follows:\n\n*   **Histone modification:** Chromatin is organized into nucleosomes, which consist of a segment of DNA wrapped around 8 histone proteins. Modification of histones via acetylation, phosphorylation, or methylation can alter the availability of DNA for transcription, leading to increased or decreased gene expression. Histone modification allows tumors to increase prosurvival gene expression and reduce cell cycle arrest/apoptosis gene expression.\n*   **Transcription factor expression:** Transcription factors are activated by cell-surface ligand binding or by phosphorylation. Activated transcription factors travel to the nucleus and bind to the promoter/enhancer region of a specific gene, which alters RNA polymerase binding and subsequent gene expression. Tumors overexpress surface receptors (eg, HER2) that generate pro-survival transcription factors and underexpress surface receptors that generate cell cycle arrest/apoptotic signals.\n*   **CpG modifications:** Promoter regions typically contain a section of 200-2000 base pairs that primarily contain a cytosine followed a guanosine. **Methylation** of the CpG region **silences** the adjacent gene; neoplasms often methylate CpG promoter regions adjacent to genes that slow growth.\n\nAs part of oncogenesis, many **glioblastomas methylate** the CpG region adjacent to the O6-methylguanine-DNA methyltransferase (*MGMT*) gene, which generates a protein that **repairs damaged DNA** (eg, converts O6-methylguanine [a naturally occurring alkylation product] back to guanine). Although silencing *MGMT* creates a more permissive environment for DNA mutations to drive cancer growth, it also makes the cell more susceptible to **alkylating chemotherapy** (eg, temozolomide), since alkylating agents cause DNA damage that cannot be effectively repaired without *MGMT*.\n\n**(Choice A)** Mutation of tumor suppressing genes (eg, *BAX*) that trigger apoptosis or cell cycle arrest promotes oncogenesis. However, *MGMT* is not an apoptotic gene.\n\n**(Choice B)** As part of oncogenesis, tumors often reduce major histocompatibility complex class I expression, lowering the ability of cytotoxic T cells to recognize the abnormal proteins generated by cancerous cells. This process is not mediated by *MGMT*.\n\n**(Choice D)** Increased telomerase activity helps promote cancer cell longevity; telomerase activity is frequently increased in tumors, but it is not mediated by *MGMT*.\n\nEducational objective:\nCancer cells alter expression of genes controlling survival and replication by histone modification, transcription factor expression, and CpG methylation. Methylation of the CpG region adjacent to the *MGMT* gene, which produces an enzyme that repairs DNA, makes tumor cells much more susceptible to alkylating chemotherapy.",
    "zh": "肿瘤发生发展会产生促进细胞生长和存活的基因改变。虽然这部分由抑癌基因（例如，p53）的失活基因突变介导，但大部分肿瘤发生是由未突变基因的*表达改变*介导的，如下所示：\n\n*   **组蛋白修饰：** 染色质被组织成核小体，核小体由一段包裹在 8 个组蛋白周围的 DNA 组成。通过乙酰化、磷酸化或甲基化修饰组蛋白可以改变 DNA 用于转录的可用性，从而导致基因表达的增加或减少。组蛋白修饰使肿瘤能够增加促生存基因的表达并减少细胞周期停滞/细胞凋亡基因的表达。\n*   **转录因子表达：** 转录因子通过细胞表面配体结合或磷酸化激活。激活的转录因子移动到细胞核并与特定基因的启动子/增强子区域结合，从而改变 RNA 聚合酶的结合和随后的基因表达。肿瘤过度表达产生促生存转录因子的表面受体（例如，HER2）并低表达产生细胞周期停滞/凋亡信号的表面受体。\n*   **CpG 修饰：** 启动子区域通常包含一段主要包含胞嘧啶后接鸟嘌呤的 200-2000 个碱基对。CpG 区域的**甲基化**会**沉默**相邻基因；肿瘤通常会甲基化与减缓生长的基因相邻的 CpG 启动子区域。\n\n作为肿瘤发生的一部分，许多**胶质母细胞瘤会甲基化** O6-甲基鸟嘌呤-DNA 甲基转移酶 (*MGMT*) 基因附近的 CpG 区域，该基因产生一种**修复受损 DNA** 的蛋白质（例如，将 O6-甲基鸟嘌呤[一种天然存在的烷基化产物]转化为鸟嘌呤）。尽管沉默 *MGMT* 为 DNA 突变驱动癌症生长创造了更有利的条件，但它也使细胞更容易受到**烷化化疗**（例如，替莫唑胺）的影响，因为烷化剂会导致 DNA 损伤，而没有 *MGMT* 就无法有效修复。\n\n**(选项 A)** 触发细胞凋亡或细胞周期停滞的抑癌基因（例如，*BAX*）的突变会促进肿瘤发生。然而，*MGMT* 不是凋亡基因。\n\n**(选项 B)** 作为肿瘤发生的一部分，肿瘤通常会降低主要组织相容性复合物 I 类分子的表达，从而降低细胞毒性 T 细胞识别癌细胞产生的异常蛋白质的能力。这个过程不由 *MGMT* 介导。\n\n**(选项 D)** 增加的端粒酶活性有助于促进癌细胞的寿命；肿瘤中端粒酶活性经常增加，但它不由 *MGMT* 介导。\n\n教育目标：\n癌细胞通过组蛋白修饰、转录因子表达和 CpG 甲基化来改变控制生存和复制的基因的表达。与产生修复 DNA 酶的 *MGMT* 基因相邻的 CpG 区域的甲基化使肿瘤细胞更容易受到烷化化疗的影响。"
  },
  "summary": {
    "en": "This question tests knowledge of the function of the MGMT gene and how its methylation status affects cancer cell sensitivity to alkylating chemotherapy. It also assesses understanding of epigenetic modifications and their role in cancer development. \n\nThe key to solving this question is recognizing that MGMT repairs DNA damage caused by alkylating agents. Methylation of the MGMT promoter silences the gene, preventing DNA repair and making cells more vulnerable to chemotherapy. Therefore, the correct answer is the one that describes DNA repair.",
    "zh": "这个问题测试了对 MGMT 基因功能的了解，以及其甲基化状态如何影响癌细胞对烷化化疗的敏感性。它还评估了对表观遗传修饰及其在癌症发展中的作用的理解。\n\n解决这个问题的关键是认识到 MGMT 修复烷化剂引起的 DNA 损伤。MGMT 启动子的甲基化会沉默该基因，阻止 DNA 修复，并使细胞更容易受到化疗的影响。因此，正确的答案是描述 DNA 修复的那个。"
  },
  "tags": "MGMT; DNA repair; Glioblastoma multiforme; Alkylating chemotherapy; Epigenetics; Methylation; Cancer; Oncology; Gene silencing",
  "category": "Bio",
  "question_id": "21310",
  "has_exhibits": true,
  "exhibit_count": 1,
  "exhibit_files": [
    "image1.jpg"
  ],
  "folder_path": "C:\\Datas\\usmle\\step1\\clip\\Bio & Statistics 23\\21310",
  "extracted_at": "2025-11-05T11:15:48.776440",
  "extraction_config": {
    "temperature": 0.1,
    "top_k": 1,
    "prompt_strategy": "standard"
  },
  "translated_at": "2025-11-07T16:24:22.010027",
  "translation_model": "gemini-2.0-flash-lite",
  "embedding_model": "models/embedding-001",
  "embedding_dimension": 768
}